- Ciba has launched a new estrogen transdermal patch onto the US market. The product, called Vivelle, was developed by drug delivery specialist Noven and is the first of this firm's products to win through to commercialization. Noven notes that Vivelle is administered just twice-weekly and is the only estrogen patch to be available in four dosage strengths, allowing physicians to maintain their patients on the lowest possible dose. Initially approved for estrogen replacement therapy in post-menopausal women, Vivelle is also being studied for the prevention of postmenopausal osteoporosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze